Chemistry:Setrobuvir

From HandWiki
Short description: Chemical compound
Setrobuvir
Setrobuvir.svg
Names
Preferred IUPAC name
N-(3-{(4aR,5S,8R,8aS)-1-[(4-Fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2,4a,5,6,7,8,8a-octahydro-5,8-methanoquinolin-3-yl}-1,1-dioxo-1,4-dihydro-1λ6,2,4-benzothiadiazin-7-yl)methanesulfonamide[1]
Other names
ANA-598; ANA598
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
KEGG
UNII
Properties
C25H25FN4O6S2
Molar mass 560.62 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is ☑Y☒N ?)
Infobox references
Tracking categories (test):

Setrobuvir (also known as ANA-598) was an experimental drug candidate for the treatment of hepatitis C that was discovered at Anadys Pharmaceuticals, which was acquired by Roche in 2011; Roche terminated development in July 2015.[2][3] It was in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1.[3]

Setrobuvir works by inhibiting the hepatitis C enzyme NS5B, an RNA polymerase.[4]

References

  1. "International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names: List 68". World Health Organization. p. 322. https://www.who.int/medicines/publications/druginformation/innlists/RL68.pdf. 
  2. "Setrobuvir" (in en). AdisInsight. http://adisinsight.springer.com/drugs/800014226. Retrieved 28 August 2017. 
  3. 3.0 3.1 "HCV Followup: Anadys Acquired for Active Antiviral". Chemical & Engineering News. October 24, 2011. http://cenblog.org/the-haystack/2011/10/anadys-acquired/. 
  4. Ruebsam, F; Murphy, DE; Tran, CV; Li, LS; Zhao, J; Dragovich, PS; McGuire, HM; Xiang, AX et al. (2009). "Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase". Bioorganic & Medicinal Chemistry Letters 19 (22): 6404–12. doi:10.1016/j.bmcl.2009.09.045. PMID 19818610.